医药生物行业中报解读：创新能力成关键，公司投资评级买入和增持，市场走势向上。

今年医药生物行业中报解读显示，工业增速趋于下滑，但创新能力仍是主要关注点。最近一年行业指数走势呈现波动，在下跌和反弹中展现出市场的不确定性和变化。财通证券研究所对一些重点公司的投资评级为买入和增持，其中东诚药业、欧普康视、华大基因、鱼跃医疗和康弘药业等公司在市值、收盘价和未来三年预期收益等方面表现优异。行业的中性投资评级说明了市场对整体行业的谨慎态度，但对个别优质公司的看好依然存在。在瞄准市场的同时，投资者需密切关注行业政策、技术创新和市场需求等因素，以实现更好的投资回报。Medical biology industry industry report interpretation: industrial growth rate stepping down, the main theme is still to look at innovation ability -0905-Caitong Securities-Page 19.pdf;Medical biology industry industry report interpretation: industrial growth rate stepping down, the main theme is still to look at innovation ability-0905-Caitong Securities-Page 19.pdf;2 Recent trends of industry indexes -26%-17%-9%0%9%17%26%34%2018-092019-012019-05 medical biology Shanghai stock index Shenzhen Stock index industry special report company research Caitong Securities Research Institute investment Rating: Neutral (maintain) Table 1: Key company investment ratings Code Company total market value (100 million yuan) closing price (09.04) EPS (yuan) PE investment rating 2018A 2019E 2020E 2018A 2019E 2020E 002675 Dongcheng Pharmaceutical 103.65 12.92 0.35 0.49 0.63 36.91 26.37 20.51 buy 300595 Opcon Vision 182.15 45.10 0.54 0.75 1.12 83.52 60.13 40.27 buy 300676 BGI Genomics 283.47 70.85 1.11 1.35 1.66 63.83 52.48 42.68 hold 002223 Fish Leap Medical 221.65 22.11 0.73 0.90 1.12 30.29 24.57 19.74 buy 002773 Kanghong Pharmaceutical 318.54 36.38 1.17 1.53 2.00 31.09 23.78 18.;"